Acadia Pharma (ACAD): Offering Bridges Commercial Activities To 2019 - Piper Jaffray

August 16, 2016 7:03 AM EDT
Get Alerts ACAD Hot Sheet
Price: $23.72 -6.39%

Rating Summary:
    8 Buy, 5 Hold, 0 Sell

Rating Trend: Down Down

Today's Overall Ratings:
    Up: 26 | Down: 29 | New: 38
Trade ACAD Now!
Join SI Premium – FREE

Get access to the best calls on Wall Street with's Ratings Insider Elite. Get your Free Trial here.

Piper Jaffray analyst, Charles Duncan, reiterated his Overweight rating on shares of Acadia Pharmaceuticals (NASDAQ: ACAD) after ACADIA, yesterday, completed an offering of ~6M shares, raising $188M in net proceeds and pro-forma cash to ~$545M. The analyst believes this offering means the company’s clinical and commercial activities are well-funded into 1H19.

During this time, he expected ACADIA to make significant progress on the NUPLAZID commercial launch in the US and submit a marketing application in the EU. He believes the company can produce positive, potentially pivotal-stage data in AD agitation and advance NUPLAZID in a third possible indication such as schizophrenia or LBD.

Overall, he views the strengthened balance sheet as a positive in terms of supporting the marketing efforts needed for a successful PDP launch and funding clinical development to generate upside additional large-market neuro-psych indications. In advance of increased visibility on early traction in PDP, Phase II ADP data, and a Phase II/III ADA trial start by YE16,

No change to the price target of $44.00

For an analyst ratings summary and ratings history on Acadia Pharmaceuticals click here. For more ratings news on Acadia Pharmaceuticals click here.

Shares of Acadia Pharmaceuticals closed at $32.82 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Analyst EPS View

Related Entities

Piper Jaffray, Charles Duncan

Add Your Comment